查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
創新的契約模式:特殊疾病及罕見疾病治療藥的打入市場策略的重新定義
市場調查報告書
商品編碼
1741561

創新的契約模式:特殊疾病及罕見疾病治療藥的打入市場策略的重新定義

Innovative Contracting Models: Redefining Market Access Strategies for Specialty and Rare Disease Drugs
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入探討了創新合約在製藥業的策略運用，全面分析了何時以及如何有效地利用創新合約來確保市場進入。報告深入分析了創新合約的現狀，並重點介紹了在哪些條件下創新合約最可行、最有利。

您將更了解創新合約面臨的課題和機遇，包括其在腫瘤學和基因療法等高成本療法中的應用。報告還探討了預測分析和人工智慧在製定合約策略中的作用，並強調了成功實施所需的實際考慮因素。在行業專家的貢獻下，本報告為製藥專業人士提供了應對創新合約複雜性和優化市場進入策略的知識。

關鍵問題

  • 1.創新合約的主要發展和市場趨勢是什麼？
  • 2.企業如何判斷創新合約何時是可行的市場進入選擇？
  • 3.哪些標準能讓專家有資格就創新合約提供見解？
  • 4.包括美國和歐洲在內的不同市場如何看待創新合約？
  • 5.創新合約面臨哪些課題與機會？
  • 6.企業如何利用創新合約優化其市場進入策略？

主要企業

  • Bristol Myers Squibb
  • CSL Behring
  • Lyfegen
  • Novartis
  • Novartis Gene Therapies
  • Prescient
  • Roche
  • Verpora

部分列表參與專家

  • Verpora 創新承包副總裁，常駐英國，業務涵蓋全球
  • Prescient 真實世界證物副總裁，常駐英國，業務遍及全球
  • 市場准入：2023 年美國前 30 家製藥公司（以收入計算）

方法論

檔案報告是基於獨立且簡潔的分析，這些分析源自於專有產業研究以及對產業思想領袖的深入訪談。報告深入分析了製藥企業高管需要了解的關鍵發展和市場趨勢，以應對未來的機會和課題。每份報告的重點都基於對二手文獻的回顧和已發現的知識差距。基於這些初步研究，我們創建了基於證據、專家指導的討論指南，以確保調查能夠解答最重要的問題。此外，我們制定了嚴格的篩選標準，以確保受訪者擁有足夠的經驗、知識和資格就該主題發表意見。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供詳盡且切實可行的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助您掌握新興趨勢，有​​效應對複雜課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖 (KOL) 的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家獨家訪談和數據，以及持續的市場監測，讓您全面了解市場動態。我們的報告涵蓋 40 多個活躍的疾病領域，包含包括關鍵意見領袖洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入等領域問題的看法，使您能夠做出更明智的數據驅動決策，從而在快速變化的行業中保持競爭力。

簡介目錄

This report delves into the strategic use of innovative contracting within the pharmaceutical industry, offering a comprehensive analysis of when and how these contracts can be effectively utilised to secure market access. It provides insights into the current landscape of innovative contracting, highlighting the conditions under which these agreements are most viable and beneficial.

Gain an understanding of the challenges and opportunities associated with innovative contracts, including their application in high-cost treatments like oncology and gene therapies. The report also explores the role of predictive analytics and AI in shaping contracting strategies and addresses the practical considerations necessary for successful implementation. With contributions from industry experts, this report equips pharmaceutical professionals with the knowledge to navigate the complexities of innovative contracting and optimise their market access strategies.

Key Questions Answered:

  • 1. What are the significant developments and market trends in innovative contracting?
  • 2. How can companies identify when an innovative contract is a viable market access option?
  • 3. What criteria qualify experts to provide insights on innovative contracting?
  • 4. How do different markets, including Europe and the US, approach innovative contracting?
  • 5. What are the challenges and opportunities associated with innovative contracting?
  • 6. How can companies optimise their market access strategies using innovative contracts?

Key Companies:

  • Bristol Myers Squibb
  • CSL Behring
  • Lyfegen
  • Novartis
  • Novartis Gene Therapies
  • Prescient
  • Roche
  • Verpora

Partial List of Participating Experts:

  • Vice President, Innovative Contracting, Verpora, based in the UK but covering the globe
  • Vice President, Real World Evidence, Prescient, based in the UK but covering the globe
  • Market Access, at a top 30 pharmaceutical company by 2023 global sales, based in the US

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.